A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy

References

• SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• GuitarteC, AlagkiozidisI, MizeB, StevensE, SalameG, LeeYC. Glassy cell carcinoma of the cervix: a systematic review and meta-analysis. Gynecol Oncol. 2014;133(2):186–191. doi:10.1016/j.ygyno.2014.01.04824503463
   PubMed Web of Science ®Google Scholar
• TewariKS, SillMW, LongHJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–743. doi:10.1056/NEJMoa130974824552320
   PubMed Web of Science ®Google Scholar
• ChuaiY, RizzutoI, ZhangX, et al. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. Cochrane Database Syst Rev. 2021;3:CD013348.33661538
   PubMed Web of Science ®Google Scholar
• HaibeY, KreidiehM, El HajjH, et al. Resistance mechanisms to anti-angiogenic therapies in cancer. Front Oncol. 2020;10:221.32175278
   PubMed Web of Science ®Google Scholar
• SyedYY. Anlotinib: first global approval. Drugs. 2018;78(10):1057–1062. doi:10.1007/s40265-018-0939-x29943374
   PubMed Web of Science ®Google Scholar
• LinB, SongX, YangD, BaiD, YaoY, LuN. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 2018;654:77–86. doi:10.1016/j.gene.2018.02.02629454091
   PubMed Web of Science ®Google Scholar
• HanB, LiK, WangQ, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.303930098152
   PubMed Web of Science ®Google Scholar
• SongY, XiaoJ, FangW, et al. The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. Cancer Biol Med. 2021;18(2):562–568. doi:10.20892/j.issn.2095-3941.2020.0187
   PubMed Web of Science ®Google Scholar
• LiS. Anlotinib: a novel targeted drug for bone and soft tissue sarcoma. Front Oncol. 2021;11:664853. doi:10.3389/fonc.2021.66485334094958
   PubMed Web of Science ®Google Scholar
• LiD, ChiY, ChenX, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin Cancer Res. 2021;27(13):3567–3575. doi:10.1158/1078-0432.CCR-20-295033832949
   PubMed Web of Science ®Google Scholar
• CuiQ, HuY, MaD, LiuH. A retrospective observational study of anlotinib in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Drug Des Devel Ther. 2021;15:339–347. doi:10.2147/DDDT.S286529
   PubMed Web of Science ®Google Scholar
• ShenG, ZhengF, RenD, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. doi:10.1186/s13045-018-0664-730231931
   PubMed Web of Science ®Google Scholar
• YangH, ChenM, MeiZ, XieC, ZhouY, QiuH. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: a retrospective study. Cancer Med. 2021;10(13):4282–4290. doi:10.1002/cam4.396633987959
   PubMed Web of Science ®Google Scholar
• ZhangL, ChenL, YuH. Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients. Invest New Drugs. 2020;38(4):1186–1191. doi:10.1007/s10637-019-00858-531637668
   PubMed Web of Science ®Google Scholar
• YuJ, XuZ, LiA, et al. The efficacy and safety of apatinib treatment for patients with metastatic or recurrent cervical cancer: a retrospective study. Drug Des Devel Ther. 2019;13:3419–3424. doi:10.2147/DDDT.S214743
   PubMed Web of Science ®Google Scholar
• SuM, GaoY, YeX, et al. Clinical value of apatinib as a salvage treatment in patients with chemo-refractory advanced cervical cancer. Onco Targets Ther. 2019;12:9707–9713. doi:10.2147/OTT.S23040632009803
   PubMed Web of Science ®Google Scholar
• XiaoY, ChengH, WangL, YuX. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study. J Gynecol Oncol. 2020;31(1):e2. doi:10.3802/jgo.2020.31.e231788992
   PubMed Web of Science ®Google Scholar
• LiN, WangZ, YuanG, et al. An oral small molecule VEGFR2 inhibitor, apatinib, in patients with recurrent or refractory cervical cancer: a real world study. J Oncol. 2020;2020:3852373. doi:10.1155/2020/385237332655637
   PubMed Web of Science ®Google Scholar
• LanC, ShenJ, WangY, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2020;38(34):4095–4106. doi:10.1200/JCO.20.0192033052760
   PubMed Web of Science ®Google Scholar
• FolkmanJ, MerlerE, AbernathyC, WilliamsG. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133(2):275–288. doi:10.1084/jem.133.2.2754332371
   PubMed Web of Science ®Google Scholar
• van BeijnumJR, Nowak-SliwinskaP, HuijbersEJ, ThijssenVL, GriffioenAW. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev. 2015;67(2):441–461. doi:10.1124/pr.114.01021525769965
   PubMed Web of Science ®Google Scholar
• AlldredgeJK, TewariKS. Clinical trials of antiangiogenesis therapy in recurrent/persistent and metastatic cervical cancer. Oncologist. 2016;21(5):576–585. doi:10.1634/theoncologist.2015-039327026677
   PubMed Web of Science ®Google Scholar
• MonkBJ, Mas LopezL, ZarbaJJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28(22):3562–3569. doi:10.1200/JCO.2009.26.957120606083
   PubMed Web of Science ®Google Scholar
• MackayHJ, TinkerA, WinquistE, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010;116(2):163–167. doi:10.1016/j.ygyno.2009.08.01219740535
   PubMed Web of Science ®Google Scholar
• LuKV, ChangJP, ParachoniakCA, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012;22(1):21–35. doi:10.1016/j.ccr.2012.05.03722789536
   PubMed Web of Science ®Google Scholar
• MooreDH, BlessingJA, McQuellonRP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22(15):3113–3119. doi:10.1200/JCO.2004.04.17015284262
   PubMed Web of Science ®Google Scholar
• XuQ, ChenC, SunY, et al. 865P A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC). Ann Oncol. 2020;31:S640. doi:10.1016/j.annonc.2020.08.1004
   Web of Science ®Google Scholar
• PalakurthiS, KuraguchiM, ZacharekSJ, et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol Res. 2019;7(9):1457–1471. doi:10.1158/2326-6066.CIR-18-059531331945
   PubMed Web of Science ®Google Scholar
• LiuS, QinT, LiuZ, et al. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11(5):309. doi:10.1038/s41419-020-2511-332366856
   PubMed Web of Science ®Google Scholar
• MonkBJ, SillMW, BurgerRA, GrayHJ, BuekersTE, RomanLD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27(7):1069–1074. doi:10.1200/JCO.2008.18.904319139430
   PubMed Web of Science ®Google Scholar
• SchefterTE, WinterK, KwonJS, et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012;83(4):1179–1184. doi:10.1016/j.ijrobp.2011.10.06022342094
   PubMed Web of Science ®Google Scholar